Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.02 +0.65 (+1.27%)

Streaming Delayed Price Updated: 3:16 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients

May 23, 2025

From Genentech

Via Business Wire

FDA Approves Genentech’s Susvimo for Diabetic Retinopathy

May 22, 2025

From Genentech

Via Business Wire

The Smartest Vanguard ETF to Buy With $500 Right Now ↗

May 21, 2025

Via The Motley Fool

Topics ETFs

Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

May 20, 2025

From Genentech

Via Business Wire

Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price ↗

May 16, 2025

Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.

Via Investor's Business Daily

Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda ↗

May 15, 2025

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.

Via Benzinga

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 ↗

May 14, 2025

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.

Via Benzinga

FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases ↗

May 14, 2025

FDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes $335 million upfront.

Via Benzinga

Why Weight-Loss Developer Stocks Tumbled on Tuesday ↗

May 13, 2025

Via The Motley Fool

Topics Government

Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17% ↗

May 13, 2025

Roche's APHINITY study shows promising results for HER2-positive breast cancer treatment with Perjeta regime

Via Benzinga

Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer

May 13, 2025

From Genentech

Via Business Wire

Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say ↗

May 12, 2025

JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting...

Via Stocktwits

Topics ETFs Government Stocks

S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform ↗

May 12, 2025

It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.

Via Investor's Business Daily

Topics Government Stocks

Roche and Genentech Announce New North Carolina Manufacturing Facility

May 12, 2025

From Genentech

Via Business Wire

Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots ↗

May 12, 2025

Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space.

Via Benzinga

Topics Artificial Intelligence

Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket ↗

May 12, 2025

What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription...

Via Benzinga

Topics Government

Down Nearly 20%: Should You Buy the Dip on Eli Lilly? ↗

May 08, 2025

Via The Motley Fool

Topics Earnings Government World Trade

The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low ↗

May 07, 2025

Sarepta stock plummeted Wednesday on a "double whammy" that includes its trimmed 2025 sales outlook and a critical FDA appointment.

Via Investor's Business Daily

Topics Death

FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight ↗

May 06, 2025

FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing.

Via Benzinga

3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.

April 28, 2025

See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion.

Via MarketBeat

Topics Artificial Intelligence Economy Government

New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission

April 25, 2025

From Genentech

Via Business Wire

Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed ↗

April 24, 2025

Roche rode its pharmaceuticals growth to a sales beat, while Sanofi's report was more complicated.

Via Investor's Business Daily

Topics Earnings Government

Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs ↗

April 22, 2025

Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states.

Via Benzinga

Roche's $50 Billion US Investment Commitment Includes New Facilities, 12,000 Jobs, Expanded R&D Hubs As Drug Tariffs Loom ↗

April 22, 2025

Roche plans $50B investment in U.S. for manufacturing & research, as potential drug tariffs loom. Move to create 12,000 jobs & increase exports

Via Benzinga

Topics World Trade

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? ↗

April 14, 2025

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.

Via Benzinga

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight ↗

April 11, 2025

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells.

Via Benzinga

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success ↗

April 10, 2025

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.

Via Benzinga

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗

April 09, 2025

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Via Benzinga

Topics Government Supply Chain World Trade

Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today ↗

April 09, 2025

Might the tariff risk for pharmaceutical stocks be less than you think?

Via The Motley Fool

Topics Government World Trade

Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2 ↗

April 04, 2025

Roche's trontinemab data showed dose-dependent amyloid reduction in Alzheimer's patients, while its Elecsys pTau181 test aims for European launch in 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.